TTrialPathMatch Me to Trials
← Back to trials
RecruitingARDS

Lateral Positioning and Prone Positioning in ARDS Patients

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Lateral (30°) and alternating positioning (change of side every 30 minutes) carried out on specific beds, could be an alternative or complement to prone positioning (PP) in ARDS patients. The combination of lateralization in prone position has not been studied. The dynamic created by lateralization could allow better overall ventilation during PP, thus making it possible to further improve oxygenation. The main objective of this prospective, bicentric, open, single group study with repeated measures will be to demonstrate that the addition of repeated 30-minute periods of 30° lateralization improves pulmonary aeration in the supine and prone positions in patients with moderate to severe ARDS.

Sponsor: Centre Hospitalier de Bastia

You may qualify if…

  • ✓ Age of at least 18 years
  • ✓ ARDS evolving for less than 5 days with a PaO2/FiO2 ratio (P/F ratio) \< 150 after optimization of PEEP (P/V curve, R/I ratio), curarization and without prior use of the PP since orotracheal intubation.
  • ✓ Obtained written consent of the patient, one of his relatives or the previously designated trusted person. As soon as possible, the patient will be informed and his written consent will be obtained
  • ✓ Beneficiary of health insurance coverage
  • ✓ Possibility of participating in any other studies whose evaluation criteria do not interfere with those of the study
  • ✓ Non-inclusion criteria:
  • ✓ Patients with at least one of the following criteria will not be eligible:
  • ✓ Refusal to participate

You may not qualify if…

  • ✕ \- Patients who will be unable to complete the 25-hour intervention due to worsening requiring ECMO, death or organizational problems will be excluded from the analysis.

Source: ClinicalTrials.gov · NCT06647784 · last updated 2025-05-15